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ABSTRACT
Rational drug design is a powerful method in which new and innovative therapeutics can
be designed based on knowledge of the biological target aiming to provide more
efficacious and responsible therapeutics. Understanding aspects of the targeted biological
agent is important to optimize drug design and preemptively design to slow or avoid drug
resistance. Chagas disease, an endemic disease for South and Central America and
Mexico is caused by Trypanosoma cruzi, a protozoan parasite known to consist of six
separate genetic clusters or DTUs (discrete typing units). Chagas disease therapeutics are
problematic and a call for new therapeutics is widespread. Many researchers are working
to use rational drug design for developing Chagas drugs and one potential target that
receives a lot of attention is the T. cruzi trans-sialidase protein. Trans-sialidase is a
nuclear gene that has been shown to be associated with virulence. In T. cruzi, transsialidase (TcTS) codes for a protein that catalyzes the transfer of sialic acid from a
mammalian host coating the parasitic surface membrane to avoid immuno-detection.
Variance in disease pathology depends somewhat on T. cruzi DTU, as well, there is
considerable genetic variation within DTUs. However, the role of TcTS in pathology
variance among and within DTU’s is not well understood despite numerous studies of
TcTS. These previous studies include determining the crystalline structure of TcTS as
well as the TS protein structure in other trypanosomes where the enzyme is often
inactive. However, no study has examined the role of natural selection in genetic
variation in TcTS. In order to understand the role of natural selection in TcTS DNA
sequence and protein variation, we sequenced 540 bp of the TcTS gene from 48 insect
vectors. Because all 48 sequences had multiple polymorphic bases, we examined cloned
sequences from two of the insect vectors. The data are analyzed to understand the role of
natural selection in shaping genetic variation in TcTS and interpreted in light of the
possible role of TcTS as a drug target.
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Chapter 1: Introduction to Chagas
A Brief History of Chagas Disease and Control Efforts
Chagas disease was first described in 1909 by its namesake Dr. Carlos Chagas,
and his description remains one of the most complete initial descriptions of any tropical
disease [1]. Carlos Chagas was able to identify the infecting parasite, the vector mode of
transmission, possible mammalian host species, and clinical symptoms. Despite the
initial complete description, over a 100 years later Chagas disease remains one of the
most impactful neglected diseases in Latin America [1]. As well, the burden of Chagas
continues to grow and with the modern mobility of humans, Chagas exists globally, with
an estimated 8 to 10 million people infected worldwide [2].
The protozoan family Trypanosoma contains pathogenic and non-pathogenic
species [3] including Trypanosoma cruzi, the causative agent of Chagas Disease, and
Trypanosoma brucei, the etiological agent of African Sleeping Sickness. The main
transmission mode for Chagas is through insect vectors of the subfamily Triatominae [4].
The T. cruzi life cycle is often split into two phases: the insect vector cycle and the
mammalian host cycle. The vector cycle includes the parasite being introduced to the
vector through a blood meal of an infected mammal host, where the parasite is taken up
as trypomastigotes [5]. Once inside the insect, the parasite progresses to the midgut as an
epimastigote, where it proliferates, eventually progressing to the hindgut as metacyclic
trypomastigote [5]. When the triatomine takes a subsequent blood meal, the parasite
passes from the hindgut and is deposited in the feces onto the skin of the mammal blood
source. This marks the transition from the insect vector and to the pathogenic human
1

cycle where the metacyclic trypomastigotes may enter the bite-wound site or through a
mucous membrane into the host bloodstream. Once a mammal is infected the
trypomastigotes enter cells, and transform into amastigotes which continue to proliferate
within cells of infected tissues [5].
Understanding the parasite life-cycle allows for two distinct paths for managing
the impact and reach of Chagas disease, one being through vector control. The second
path, the topic of this thesis, is exploring possible pharmacological advancements
specifically targeting the parasite within mammalian hosts through new drugs.
Vector control has been a primary method for reducing Chagas disease in many
of the endemic countries in South and Central America and Mexico and has been
especially effective in the South American countries where large multidisciplinary efforts
were made. One large effort to reduce Chagas transmissions was the Southern Cone
Initiative which was a coordinated effort between six South American countries
(Argentina, Bolivia, Brazil, Chile, Paraguay, and Uruguay) by the World Health
Organization (WHO) [6]. One of the main goals of the Southern Cone Initiative was to
eradicate the main insect vector for the region, Triatoma infestans, largely through
insecticide spraying of infested and at-risk dwellings [7]. The initiative was considered
successful in most of the Southern Cone countries, drastically reducing populations of T.
infestans and thus effectively reducing vector borne transmission and the associated
economic and societal burdens of Chagas in these countries [8].
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However, while successful, the Southern Cone Initiative does have several
issues that provide reservations to its long term effect and future direction. One of the
largest issues that needs to be addressed is possible long term effects on human or
environmental health from the widespread insecticide use. Over 2 million houses were
sprayed with insecticides ranging from chlorinated hydrocarbons to pyrethoids.
Additionally in some regions insecticide laden paints were used outside and inside houses
[7]. The most commonly used insecticide was lindane, a chlorinated hydrocarbon, the
safety of which in agriculture and pharmacology has been widely debated. This has
resulted in the chemical being banned, except for occasional pharmacological
applications (e.g., third line treatment for lice), in over 50 countries including the United
States [9]. Disregarding the possible benefits for reducing vector transmission of Chagas
disease, the human toxicity and environmental pollution associated with lindane and
other insecticides should be considered when evaluating their costs and benefit, in
Chagas vector control.
Other potential challenges of the Southern Cone Initiative include the
reemergence of T. infestans populations. In regions where T. infestans was originally
endemic without recurrent insecticide spraying the vector is able to repopulate areas
where it was previously removed [10]. This not only undermines the goal of the initiative,
but it also may be a mechanism for the insects to develop insecticide resistance requiring
the use of higher doses or different insecticides, potentially adding to human and
environmental health impacts.
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Vector control is often recognized as interrupting vector borne transmission
rather than disease eradication or permanent reduction because of the potential for vector
reemergence or ecological succession (i.e., other vector species replacing a previously
common vector species) [8]. Vector control through insecticide use is challenging as a
large-scale solution for the reasons mentioned above and because there simply is not one
vector for Chagas transmission. There are over 140 species, all within the subfamily
Triatominae. Epidemiologically important vector species are largely regional and vector
control is complicated by many factors such as population density and the landscape of a
region as both contribute to the diversity of vector species in an area.
The last pitfall of the Southern Cone Initiative to be addressed here is that
although it reduced the rate and number of new infections, it did not address the
population of already infected Chagas patients. Pharmacological advances would address
both these issues and could be more stable long-term tools in fighting Chagas disease.
New therapeutics aimed at Chagas need to be developed to improve the ability of
clinicians to actually treat and possibly one-day cure patients of the disease. Research to
develop Chagas drugs should be seen as complimenting the progress of vector control
efforts and provide long term solutions to the existing Chagas patient population and
offer better outlooks to new Chagas patients. The current pharmacological options
available to treat Chagas revolve around two drugs Beznidadazole and Nifurtimox both
of which face similar issues in their effectiveness and ability to manage Chagas long term
[11].
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Human Pathology of Chagas Disease
Although Chagas disease in humans occurs mainly through vector transmission,
congenital infection is also possible as well as infecting through blood and organ
donations [4]. Human Chagas disease has two main phases: acute and chronic. The short
acute phase, which lasts from a few weeks to months is largely asymptomatic for many
patients. For symptomatic cases, acute Chagas can present many symptoms including
fever, edema, swollen lymph nodes (adenopathy) and localized swelling around the
parasite entry point, also known as a Chagoma or Romaña’s sign. In terms of acute
Chagas Chagomas is considered the telltale symptom of T. cruzi infection [12]. The
severity of the acute phase is contingent on many other factors including mode of parasite
acquisition, patient age, patient overall health and the infecting DTU. The predominance
of asymptomatic cases of Chagas presents a dilemma as while it is good that the patient is
not dealing with potential ill health or life-impacting symptoms, it may mask the presence
of the disease overall. This is problematic as the acute phase is the most efficacious time
for the current Chagas drugs, Nifurtimox and Benznidazole [13].
Once the disease progresses past the acute phase the parasite enters a largely
asymptomatic indeterminate phase which last 10-30 years after the initial infection. At
least 30% of patients have the reemergence of symptoms in the chronic phase [12].
Progression of chronic disease within humans is somewhat associated with the particular
genetic strain of the infecting parasite, but in many aspects is poorly understood [14].
Chagas disease that reaches the chronic phase mainly affects tissues of three organs;
cardiac, esophageal, and intestinal. For example, the strain recognized as TcI often
5

progresses to Chagasic cardiomyopathy. While other strains have also been shown to
cause Chagasic cardiomyopathy these strains have also been linked to megaesophagus
and megacolon [14]. In this way diagnosing the infecting DTU becomes important to
predict the prognosis and further development of the disease, and thus may be useful as a
diagnostic tool.
While there is diversity in symptoms, severity, and progression of the disease,
the therapeutic tools available lack diversity. Chagas disease as mentioned previously is
treated predominantly with two drug options Nifurtimox and Benznidazole, both of
which have toxic effects on the patient [15]. For example Benznidazole causes
neutropenia and Nifurtimox can cause anorexia [16]. Overall, Benznidazole has less
common but more debilitating side effects such as dermal hypersensitivity and
polyneuropathy [11]. Another issue with the availability of only these two drugs is the
possibility of T. cruzi evolving single drug resistance, and the more challenging
possibility of cross-resistance between the drugs. One of the proposed contributing
factors to the evolution of drug resistance is the inability to complete treatment regimens.
A typical Nifurtimox course is 10mg/kg/day for 60 or 120 days, the long time frame,
coupled with the side effects of the drug courses have the consequence that drug
treatments are often abandoned early [16]. Compounding this issue, studies have shown
cross resistance, the development of resistance to Nifurtimox by T. cruzi includes crossresistance to Benznidazole, effectively removing both treatment options for those patients
[16].
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This introductory chapter has introduced some of the ecology, pharmacology and
challenges for reducing Chagas disease. The next chapter explores genetic variation in a
possible parasite protein trans-sialidase suggested as a possible drug target.
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Figure 1: Surface anchored trans-sialidase (TS) proteins on the parasite outer
membrane mediate transfer of sialic acid from the host glycoconjugate to parasite
surface mucins (sialylation) within a mammal host. The sialylated mucin provides
parasite protection from the host immune system and helps in parasite adhesion to
host cells. TS proteins shed into the host bloodsteam can interact with several cell
types leading to multiple downstream biological effects. Used with permission from
Nature Reviews: Microbiology (http://www.nature.com/nrmicro/journal/v4
/n3/box/nrmicro1351_BX1.html)
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Chapter 2: The role of natural selection in shaping genetic variation in a
promising Chagas Disease drug target: Trypanosoma cruzi trans-sialidase

Introduction
Trypanosoma cruzi is a human pathogen responsible for Chagas Disease, also
known as American Trypanosomiasis. The disease is endemic in Mexico, Central and
South America and is currently affecting an estimated 8-10 million people with another
70 million people at risk [1]. Primarily transmitted by insect vectors of the Triatominae
sub-family (Hemiptera: Reduviidae), T. cruzi displays complex genetic diversity with
resulting complexity in its pathogenic effects within and between mammalian species [2].
Various approaches have been used to characterize the diversity in T. cruzi with the
general consensus of six major subdivisions known as known as Discrete Typing Units
(DTUs) and named TcI – TcVI. A seventh DTU (TcBat), found within TcI has been
brought to recent attention, as well as a lineage found only in bats, T. cruzi marinkelli,
that forms a sister group to TcI-TcVI [3].
This heterogeneity in T. cruzi has been shown to be significant in human Chagas
Disease as certain progressions of the disease have been linked to particular DTUs. For
example, TcI has been linked to the development of Chagasic cardiomyopathies, while
other DTUs have been shown to progress to more gastrointestinal symptoms such as
megaesophagus [4].
Efforts to reduce autochronous Chagas transmission through vector control have
been remarkably effective. However, in regions where sylvatic populations exist, vector
control requires repeated use of insecticides around and within homes and such repeated
11

use of insecticides can have adverse ecological and human health effects as well as lead
to insecticide resistance [5]. Further, although vector control methods have interrupted
transmission significantly, they fail to address the growing patient population already
infected. This combination of factors means that new therapeutics are needed.
The T. cruzi trans-sialidase (TcTS) receptor gene has been suggested as a
biological target for a rationally designed Chagas drug [6-8,11-13,18]. This receptor is
essential for parasite growth, because it is a receptor it can potentially be inhibited [6],
and it has been implicated in virulence [7]. The TcTS receptor harvests sialic acid from
the mammal host, a molecule critical for eukaryotic proliferation and survival that is
produced by mammalian cells but not produced by T. cruzi. Among the
Trypanosomatidae, which includes other human pathogens such as Trypanosoma brucei
the etiological agent of African sleeping sickness, only T. cruzi is known to be unable to
produce sialic acid and thus expresses high levels of the TcTS receptor in the
trypomastigote stage (the stage infecting vertebrate blood) [7]. The TcTS receptor
captures sialic acid from the blood of its mammalian host, transferring it to surface
mucins coating its outer membrane. The sialidated molecule is important in evading
immune detection [8]. These features of TcTS make it an excellent target for Chagas
rational drug development [7].
Despite the high potential of the TcTS receptor as a target for drug design, high
throughput screens for potential TcTS inhibitors have been relatively unsuccessful. One
possible reason could be genetic diversity of the receptor [7].
The TcTS genes are part of a large superfamily of over 1400 genes containing the
conserved VTVxNVxLYNR motif [9]. These genes form eight groups, of which only
12

group 1 codes for active trans-sialidases [10] with estimates of 1-32 enzymatically active
TcTS gene copies per haploid genome [11]. Of the remaining genes about 700 are
functional but produce inactive TS, and approximately 700 are pseudogenes [7].
The TcTS protein has an N-terminal catalytic domain (amino acids 1-371) that
ends in a six bladed beta propeller, an alpha helix (amino acids 372-394) connects the
catalytic domain to the C-terminal lectin-like domain (amino acids 395-632). Another
alpha helix near the C-terminus (amino acids 614-626) is sometimes followed by a
variable repetitive (100-500 amino acids) hydrophilic, 12 residue shed acute phase
antigen (SAPA) motif [8].
Within the N-terminal catalytic domain, group I active TcTS differ from inactive
forms by a single amino acid replacement, Tyr342His. The transfer of sialic acid from
host to parasite glycoconjugates catalyzed by TcTS (Figure 2.1a) involves an additional
seven amino acids known to bind to sialic acid. During the transfer reaction, Tyr342 is
crucial in forming the covalent intermediate resulting from cleaving the sialic acid from
the host glycoconjugate (Fig 2.1b) before it is transferred to a parasite glycoconjugate
(Fig 2.1c) [12].
Identifying and further exploring the genetic diversity of TcTS is important
towards drug development since the structure and function of proteins has been shown to
be sensitive to amino acid changes anywhere in a peptide sequence, not just active
domains (e.g.,[14]), genetic variation in TcTS may affect susceptibility to inhibitors, and
may need to be considered when evaluating TcTS for rational drug design.
Rational drug design incorporates biological information and aims to create
more effective and longer lasting therapies. Since drugs act as selective agents, it is
13

important to understand the evolutionary processes acting on a drug target [15]. There are
several statistical tests to determine if DNA sequence variation results from neutral
processes, or negative or positive selection [15, 16]. Negative, or purifying selection, is
the removal of disadvantageous mutations. Positive selection, or adaptive evolution,
includes the increase in frequency of advantageous mutations as well as types of selection
important in host-parasite interactions such as balancing selection (also called
heterozygote advantage or overdominance) and negative frequency-dependent selection
(i.e., rare alleles are favored). These types of selection have different implications for a
drug target. It has been suggested that positive selection is not beneficial for a drug target
while negative selection does add to a targets justification [17].
We assessed DNA sequence and protein variability in an ~500 bp region of the
TcTS gene of T. cruzi isolated from the abdomens of Triatoma dimidiata the major insect
vector in Central America and Mexico and Triatoma nitida, a species with a more
restricted geographic range that is sometimes found in sympatry with T. dimidiata. Our
T. dimidiata specimens were from Guatemala and El Salvador, and the T. nitida from
Guatemala. We did Sanger sequencing of 48 PCR products (hereafter referred to as
PCRp). Because TcTS is a nuclear gene and insects could potentially be infected with
one or more parasite strains and also because TcTS has 1-32 copies per haploid genome,
for a subset of the insects we cloned the PCR products prior to sequencing (referred to as
the 10 cloned sequences).
The region analyzed starts in the N terminal catalytic domain (amino acids 269 to
371), extends into the alpha helix (372-394) and ends in the C-terminal lectin-like domain
(amino acids 373 to 434). This region includes four amino acids important in the binding
14

of sialic acid, Pro238, Trp312, Arg314, and Tyr342 (Table 2). The sequence data were
used to identify the DTU of T. cruzi infecting the insects and verify we were examining
sequence from the group I active TcTS subfamily. The sequence data were then analyzed
for natural selection at both the level of the gene and the level of individual amino acids.
First, the McDonald Kreitman (MK) test, which considers an entire gene or region of
DNA, was used to test for selection within homogeneous regions (catalytic vs noncatalytic) [23,24]. Second, we used Selecton, an amino acid site-specific test [26,27]. The
MK test was only appropriate for testing the cloned sequences, whereas both the cloned
and 48 PCRp sequences were examined with Selecton.

Results
The 58 new TcTS sequences from this study belong to group 1, the only one of
the eight groups in the superfamily with active TS. Examination of the cloned TcTS
sequences with the MK test indicated significant balancing selection in the catalyticdomain of the TcTS gene. The variation was not significantly different from a neutral
model of evolution for the part of the C-terminal lectin-like domain region examined. In
addition, for both the cloned and PCRp sequences, the test for selection at each individual
amino acid site found evidence of positive and negative selection within the regions
examined. Below we present the data supporting these results.
Confirmation of TcTS sequences as TS group 1
Phylogenetic analysis indicated that the sequences are from TcTS group 1 genes
that code for active TS (Fig. 2.2) with strong statistical support (100% bootstrap support).
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As expected, all 58 sequences from this study had Tyr342, the critical amino acid that
distinguishes the active and inactive forms of TS.

Tests for natural selection
The multi-locus MK test indicated the two regions of the TcTS gene were
heterogeneous (Table 1b, wMK = 2.077, c2 = 6.205, p < 0.02). We therefore analyzed each
region separately with the standard MK test.
We detected statistically significant negative and/or balancing selection in the
catalytic domain (Table 2, Neutrality index NI = 4.940, c2 = 14.348, p < 0.001).
Examination of the contingency table (Table 2) shows a higher number of nonsynonymous polymorphisms than synonymous substitutions for this region (Pn = 15 > Ps
= 8) suggesting balancing selection.
For the non-catalytic region that included the alpha helix and part of the Cterminal lectin-like domain, the pattern of variation is consistent with the neutral model
of evolution (Table 3c, Neutrality index NI = 1.091, c2 = 0.047, p > 0.05).
The test using Selecton that examined selection at each individual amino acid,
showed evidence of both positive and negative selection over the region examined (Fig
2.3). Among the 166 amino acids studied, Selecton identified 59 sites of positive
selection, including both directional and balancing selection, 81 sites of purifying
selection and 26 neutral sites. Overall the model including positive selection is a better fit
to the data than the null model that includes only purifying selection and neutral
synonymous changes (log likelihood -1227.73, delta-log-likelihood -3.35, p-value <
0.02).
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The conservation metric (Fig 2.3) provides an estimate of variation for a
particular amino acid. Over the region examined, the conservation metric ranges from 0.5
to 1, with an average value of 0.962. The catalytic domain showed higher average
conservation (0.982) than the non-catalytic region (0.930).
Selecton values span the possible range (1 indicates strongest positive, 4 is
neutral, 7 is strongest purifying). The average selection value over the region examined
was 4.361, the catalytic region was toward more purifying selection (average of 4.767)
while the non-catalytic region indicated more positive selection (average of 3.398).
With respect to the amino acids essential to catalytic activity, sites 283, 342 and
357 showed negative selection, having both high conservation values and Selecton
values. Site 314 showed evidence of positive or balancing selection indicated by high
polymorphism (low conservation) and low Selecton scores, while site 312 was neutral.
Comparison of the Selecton values of the 10 clones with the 48 PCRp sequences
shows the PCRp sequences show fewer sites of positive selection (Fig. 2.4). The selecton
results of the PCRp sequences identified only 49 positively selected sites, 26 neutral sites,
and 91 negatively selected sites. The average selecton value for the entire region
examined was 4.6506, as well using the same division in the sequence as above, the
catalytic region was more indicating of purifying selection (average of 4.9417) than the
non-catalytic region (average of 4.1746). Similarly, the average conservation score for
the entire region analyzed was 0.9564. While the catalytic domain region again showed
higher conservation (0.9776) than the non-catalytic region (0.9216).
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Discussion
In this study analyzing how natural selection and genetic variation in the TcTS
gene might affect its potential for rational drug design for our cloned sequences we found
no DNA or amino acid variation at most of the sites essential to catalytic activity,
however for one site there was significant diversifying or balancing selection. These
results are explained in detail below.
In analyzing selection on our sequences, we first confirmed through phylogenetic
analysis that our PCRp and cloned sequences represent TcTS protein group 1. This is
important since TcTS group 1 is the only group within the trans-sialidase protein
superfamily that produces active trans-sialidase.
The MK test, which was appropriate only for the cloned sequences, detected
heterogeneity in selection between the catalytic domain, which showed signs of balancing
and negative or purifying selection, and the non-catalytic portion of the protein which
was not significantly different from expectations of a neutral model of evolution.
Although the MK test detected an overall signal of balancing or negative selection
across the catalytic domain, detailed analysis of individual amino acids with Selecton
confirmed the “negative” selection detected by the MK test to be a combination of
negative and balancing selection. For the non-catalytic region of the protein, the MK test
could not reject a neutral model of evolution.
With respect to the amino acids essential to catalytic activity, three of the five
sites showed signs of negative selection, consistent with the explanation of low variation
because most mutations are deleterious and recessive and are removed by selection or
linger in the population at low frequency (e.g., sites 283, 342 and 357). However,
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although most amino acids critical to protein function are under negative selection, one
site 314 indicated balancing selection while site 312 has a neutral selecton value.
Analysis with Selecton shows quite a few amino acids under positive (balancing)
selection in the C-terminal domain, 24 showed positive selection, 12 sites neutral and 27
sites showed negative selection.
For the case of the variation at Arg314, there is variation within the clonal
sequences for one sample. However, the all other clonal samples and the 48 PCRp
sequences are conserved for this site with no DNA variation.
Viewing the Selecton values on the 3D structure can help to identify how
selection is distributed structurally. Projection of the selecton scores on the 3D structure
of the protein (Fig. 2.4) reveals that the region of the catalytic domain sequenced in this
study contains 60 of the overall 81 negatively selected sites indicating that there is strong
constraint on the TcTS structure.
A multiple sequence alignment (MSA) was constructed with the PCRp and clone
sequences combined with Genbank reference samples spanning all eight TS gene and
pseudogene groups. The MSA facilitates examination of the amino acids essential to
catalytic activity in the region sequenced in this study (S1). Among the 58 PCRp and
Clone samples there is no DNA variation for three of the amino acids essential to TS
transfer activity. In contrast, TS groups 2-8 show some significant variation at these sites.
The amino acid variation at these sites was not conserved with any discernable pattern,
that is TS groups 2 - 8 did not have distinct variation based on the respective TS group,
and no pattern was discernable based on the taxa of the sequences.
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How do these results inform rational drug design? Regions of purifying selection
are considered strong targets. We detect strong negative selection for the amino acid that
distinguishes active and inactive TcTS, Tyr342.
In contrast, regions of positive selection indicating adaptive evolution are not
desirable drug targets. This is because positively selected regions show variability and the
potential of the parasite to develop drug resistance. Drug targets should avoid positively
selected amino acids such as Arg314, an amino acid important in the carboxylation step
of TcTS activity.
Drug design should work to develop inhibitors acting specifically at sites such as
Tyr342 that are crucial to the protein function and under negative (purifying) selection.
Specificity ensures an inhibitor is acting on the desired amino acid residue and can be
measured experimentally. A promising inhibitor believed to be specific for Tyr342 could
tested by mutating or removing Tyr342 (e.g., through site-directed mutagenesis) and
determining if the inhibitor exhibits lower affinity. For example, a recent study using
drug repositioning to identify possible trypanocidal agents acting on TcTS [18] could also
test the specificity of promising compounds with respect to identified critical and
negatively selected amino acids. Trypanocidal agents specific to sites under negative
selection would be preferential for long term drug efficacy than ones specific to sites
under positive selection. Drug development for Chagas disease may consider not only
anti-parasitic drugs but also anti-virulent drugs.
In summary, this study analyzing natural selection and genetic variation in the
TcTS gene identified regions of purifying, balancing and positive selection in the TcTS
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protein. Rational drug design should consider this variation to increase the likelihood of
developing effective drugs with lower chances for the evolution of drug resistance.

Methods
Insect vectors, DNA isolation, PCR and sequencing
We examined parasites from two species of insect vectors, Triatoma dimidiata
and Triatoma nitida (Table 1). The T. dimidiata were collected from three departments
(Huehuetenango, Quiche and Jutiapa) in Guatemala and four in El Salvador (Morazan,
Santa Ana, Ahuachapan, Sonsonate). The T. nitida were from two departments in
Guatemala (Huehuetenango and Chiquimula).
The T. cruzi DNA was extracted from the last two segments of each insect
abdomen using previously described methods [19]. The PCR amplification used primers
(TS 31: TCACGCAGCGGTACGCATCCT, TS 51: GGAGGCTGTCGGCACGCTCTC)
specific to group I TS genes that make active trans-sialidases [11]. The PCR conditions
were as previously reported [11] and PCR results were confirmed via gel electrophoresis.
Samples showing the appropriate size PCR product were sequenced by a commercial
facility (Genewiz, South Plainfield, NJ).
The PCR reaction amplified 540 bp and we analyzed a fragment coding for 166
amino acids of the TcTS protein. The region analyzed includes five amino acid residues
identified as important to the function and structure of the protein (Table 2): Pro238,
Trp312, Arg314, Tyr342 and Glu357 [8] including the critical amino acid Tyr342His
that distinguishes the active and inactive forms, but not including the conserved
VTVxNVxLYNR motif [9].
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The sequence files were trimmed to 498 bp removing the primer regions and
edited using Sequencher (V5). Heterozygous peaks were evidence of polymorphism
within an insect vector. Two insect vectors were selected for cloning to resolve the
heterozygous peaks and identify haplotypes. We cloned fresh TcTS PCR product using
the pGEM-T Easy cloning kit (Promega) following the manufacturer’s instructions for
both ligation and transformation, specifically using the pGEM-T Easy Vector, T4 DNA
Ligase, and JM109 High Efficiency Competent Cells (Promega). In order to confirm the
success of the transformation both ampicillin selection and a blue-white screen were
used. Harvested white colonies were boiled to lyse the cells and extract DNA which was
then PCR- amplified and sequenced as described above. The cloned sequences are
hereafter referred to as such. The non-cloned, PCR product sequences are referred to as
PCRp hereafter.

Confirmation of TcTS sequences as TS group 1
Our cloned and PCRp sequences were combined with GenBank TcTS sequences
and other Trypanosoma species trans-sialidase sequences (Table 1) for a total of 102
sequences; 58 new from this study and 34 from Genbank. The 58 sequences from this
study include 48 PCRp sequences and 10 cloned sequences (four from one and six from a
second of the 48 PCRp sequences).

Phylogenetic analysis was used to confirm the TcTS group of the 58 sequences
new from this study by comparison with reference sequences [9]. The sequences were
aligned with ClustalW in MEGA (V7) and translated into amino acid sequences based on
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GenBank reference sequences. Alignment and translation was performed with T-Coffee
[20-22].
The sequences were analyzed in ProtTest (V2.4) to identify the best model
parameters for construction of the phylogenetic tree. RaxML(V8.0.0) was used to
construct the phylogeny within the CIPRES Science Gateway V3.3 server combined with
bootstrapping to quantify branch support. The optimal tree output was then drawn in
FigTree (V1.4.3).

Tests for natural selection
Two tests were done to determine the role of natural selection in TcTS DNA
sequence variation and evolution, specifically, the McDonald-Kretiman (MK) test [23,24]
which considers an entire gene (or portion) and Selecton, an amino acid site-specific test
[26,27]. The 10 cloned sequences were examined with both the MK test and Selecton.
Because of the ambiguous nucleotide sites, the 48 PCRp sequences could only be
examined with Selecton.
To examine the role of neutral vs selective processes for the cloned sequences we
used an online version for the MK test [23, 24]. Trypanosoma brucei group 1 TS
(AF310232) was used as the outgroup [9]. The MK test assumes homogeneity across the
gene, but because different regions of the TS gene may evolve differently, we used the
multi-locus MK test to test for heterogeneity of part of the region with the N terminal
catalytic domain (amino acids 269 to 371) compared to the region with the alpha helix
(372-394) and part of the C-terminal lectin-like domain region (amino acids 373 to 434).
Then we used the standard MK test to test for selection within homogeneous regions.
23

The MK test compares the within (polymorphic) T. cruzi non-synonymous to
synonymous (neutral) changes (Pn/Ps [19]) to the between species (divergent) T. cruzi T. brucei non-synonymous to synonymous changes (Dn/Ds) using a Chi-square test. The
Neutrality Index (NI) indicates the strength of departure from the neutral model [25]: 1
indicates the data are consistent with a neutral model of evolution, > 1 indicates either Dn
is lower than expected due to purifying selection against harmful mutations or Pn is
higher than expected due to balancing selection, and < 1 indicates Dn is high due to an
excess of fixation of non-neutral replacements from adaptive evolution or Ps is low [25].
In addition, selection at each individual amino acid site was examined and
correlated with the protein structure using the Selecton 2007 online server
(http://selecton.tau.ac.il/)[26, 27] . The test used Bayesian inference to calculate the
dN/dS ratio and used a likelihood ratio test to compare a model with positive selection
(their M8) with a null model (M8a) that assumes only purifying selection and neutral
changes. The selection values for each amino acid ranged from 1 ( strong negative
selection) to 7 (strong positive selection) and were projected on the 3D structure of the
protein using the tool First Glance in Jmol (FGiJ, http://firstglance.jmol.org, PDB 1S0I)
implemented in Selecton [26, 27].
In interpreting the results, for the MK test, NI < 1 (“positive” selection) refers to
adaptive evolution through directional selection; whereas NI > 1 (“negative” selection)
includes both purifying and balancing selection. For the Selecton test, negative selection
refers to purifying selection, while positive selection refers to adaptive evolution through
directional and balancing selection.

24

Finally, to compare the variation among the cloned sequences with the variation
among the PCRp sequences, we calculated the conservation for each amino acid, on a
scale of 0 to 1, where no variation = 1. Using the most common amino acid at each site as
the reference, each amino acid was assigned a value of 1 if was identical to the reference,
0.5 if the variation did not change the amino acid class (e.g., polar to polar or negative
charge to negative charge), and 0 if the variation caused a substitution of a different
amino acid class (e.g., polar to negative charge). The sum for each site was divided by the
number of total sequences (10 for clones and 48 for PCRp) creating a conservation score
between 0 and 1 for each site.
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Table 1: Comprehensive list of newly sequenced samples and Genbank reference samples
used in this study.
Species
Trypanosoma cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
Control Samples
T. cruzi
T. cruzi
T. cruzi
T. cruzi
Clonal Samples
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
Genbank Samples
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. cruzi
T. rangeli
T. rangeli
T. rangeli
T. rangeli
T. rangeli
T. Brucei
T. Brucei
T. carassii
T. grayi

Sample or Isolate ID
A10050-TS
A10051-TS
A10052-TS
A10053-TS
A10054-TS
A10055-TS
A10062-TS
A10063-TS
A10067-TS
A10071-TS
A10083-TS
A10227-TS
A10230-TS
A10231-TS
A10232-TS
A10250-TS
A10304-TS
A10305-TS
A10308-TS
A10311-TS
A10313-TS
A8974-TS
A9948-TS
A9950-TS
FER530-TS
FER535-TS
S234-TS
S236-TS
S238-TS
S328-TS
S354-TS
S384-TS
S445-TS
S448-TS
S455-TS
S478-TS
S486-TS
S507b-TS
TPG1019-TS
TPG891-TS
TPG892-TS
TPG1239-TS
TPG1247-TS
TPG761-TS
TPS053-TS
TPS180-TS
TPS400-TS
TPS68-TS

Vector Species
Triatoma dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
Triatoma nitida
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. nitida
T. nitida
T. nitida
T. nitida
T. nitida
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata
T. dimidiata

TS Protein Group
Country collected
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) Guatemala
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador
TS group 1 ( T. cruzi clade) ElSalvador

TcCM187-TS
TcI-TS
TcV-TS
TcVI-TS

TS group 1 (
TS group 1 (
TS group 1 (
TS group 1 (

T. cruzi clade)
T. cruzi clade)
T. cruzi clade)
T. cruzi clade)

A9950_RE1
A9950_RE2
A9950_RE3
A9950_RE7
A9950_RE8
A9950_RE12
A10055_RE2
A10055_RE4
A10055_RE5
A10055_RE7

TS group 1 (
TS group 1 (
TS group 1 (
TS group 1 (
TS group 1 (
TS group 1 (
TS group 1 (
TS group 1 (
TS group 1 (
TS group 1 (

T. cruzi clade)
T. cruzi clade)
T. cruzi clade)
T. cruzi clade)
T. cruzi clade)
T. cruzi clade)
T. cruzi clade)
T. cruzi clade)
T. cruzi clade)
T. cruzi clade)

G/TCC30
G/TCC31
CA-I
CL
CL
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
CL Brener
DOG82
DOG83
DOG84
Choachi
Choachi
TREU927
EATRO 427
ANR4

Opossum
Opossum
H. sapiens
Triatoma infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
T. infestans
Dog
Dog
Dog
R. prolixus
R. prolixus
Glossina sp
Sheep
cyprinid fish
G. palpalis gambiensis

TS group 2
TS group 2
TS group 1
TS group 7
TS group 2
TS group 2
TS group 5
TS group 2
TS group 1
TS group 3
TS group 4
TS group 6
TS group 5
TS group 2
TS group 7
TS group 4
TS group 8
TS group 1
TS group 8
TS group 6
TS group 4
TS group 2
TS group 2
TS group 2
TS group 3
TS group 2
TS group 2
TS group 2
TS group 8
TS group 5
TS group 1
TS group 1
TS group 1
TS group 1
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Brazil
Brazil
Argentina
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Brazil
Venezuela
Venezuela
Venezuela
Colombia
Colombia
Kenya
Uganda
Gambia

Department
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Huehuetenango
Quiche
Jutiapa
Jutiapa
Morazan
Morazan
SantaAna
SantaAna
SantaAna
Ahuachapan
Sonsonate
Ahuachapan
Sonsonate
Sonsonate
Sonsonate
SantaAna
SantaAna
SantaAna
Chiquimula
Chiquimula
Chiquimula
Chiquimula
Chiquimula
Chiquimula
SantaAna
SantaAna
SantaAna
SantaAna

Latitude (N)
15° 21´30.815¨
15° 21´30.815¨
15° 21´30.815¨
15° 21´30.815¨

Longitude (W)
91° 27´5.12¨
91° 27´5.12¨
91° 27´5.12¨
91° 27´5.12¨

15°24′00″
15°24′00″
15° 40´46.271¨
15° 21´30.815¨

91°58′00″
91°58′00″
91° 49´7.159¨
91° 27´5.12¨

15° 39´ 5.85¨
15° 39´ 5.85¨
15° 39´ 5.85¨
15°20′35″

91° 46´16.903¨
91° 46´16.903¨
91° 46´16.903¨
91°18′42″

15° 19´10.709¨

91° 29´ 32.358¨

14° 55´23.401¨
14° 16´44.899¨
14° 16´44.899¨
13 55' 46" N
14°04'49.0"
14°03'54.6"
14°03'54.6"
14°03'54.6"
13° 58' 0"
13° 42' 0"
13° 58' 0"
13° 45' 43"
13° 45' 43"
13° 45' 43"
13° 52´ 59¨
13° 52´ 59¨
13° 52´ 59¨
14° 41´36¨
14° 41´36¨
14° 41´36¨
14° 41´36¨
14° 41´36¨
14° 43´18.36¨
14°03'54.6"
14° 6' 0"
14° 6' 0"
14°4'45"

90° 39´45.567¨
89° 52´31.972¨
89° 52´31.972¨
88 11' 12" W
89°32'09.9"
89°31'46.3"
89°31'46.3"
89°31'46.3"
89° 49' 0"
89° 37' 0"
89° 49' 0"
89° 31' 36"
89° 31' 36"
89° 31' 36"
89° 28´ 59¨
89° 28´ 59¨
89° 28´ 59¨
89° 22´23.4¨
89° 22´23.4¨
89° 22´23.4¨
89° 22´23.4¨
89° 22´23.4¨
89° 16´31.32¨
89°31'46.3"
89° 27' 0"
89° 27' 0"
89°31'54"

Accession Number

Accession number
EF154827
AF426132
X57235
X70948
AF128843
XM_799078
XM_800086
XM_800788
XM_802406
XM_802711
XM_803072
XM_803086
XM_803518
XM_805296
XM_805583
XM_806976
XM_807627
XM_808522
XM_808523
XM_809532
XM_810613
XM_812072
XM_811278
XM_811657
XM_814626
FJ404802
FJ404803
AF426022
KC544946
KC544956
XM_842470
AF310232
AY142111
XM_009317479

Table 2: Genetic variation and selection for the TcTS amino acids essential to catalytic
activity in the region sequenced in this study.
Residue
Pro 283
Trp 312
Arg 314
Tyr 342
Glu 357

Possible Role
Transglycosylation/Hydroxylation
Aromatic Sandwich/Hydrogen Bonding
Carboxylate Fixation
Enzymatic Nucleophile
Catalysis

Clone Variation
None
None
Non-synonymous
None
None
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Clone Selection PCRp Variation
Purifying
None
Positive
None
Neutral
None
Purifying
None
Purifying
None

PCRp Selection
Purifying
Purifying
Purifying
Purifying
Purifying

Table 3: Results of multi-locus McDonald Kreitman test for the N-terminal catalytic
domain as region 1 and the alpha helix domain and C-terminal lectin like domain as region
2
McDonald Kretiman Test
Multi-locus MK Results
Region 1

Region 2

Neutral
Non-neutral
Total

Polymorphism Divergence Total
Neutrality Index
8
209.8
217.8
4.94
15
79.62
94.62
23
289.42
312.42

Neutral
Non-neutral
Total

Polymorphism Divergence Total
Neutrality Index
13
32.76
45.76
26
60.04
86.04
1.091
39
92.8
131.8

Multi-Locus Mantel-Haenszel

c2
Mantel-Haenszel
Test of homogeneity

Mantel-Haenszel
Estimator

p-value

6.205

0.012

Neutrality Index

c2

2.077

6.047

p-value
0.013
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c2
14.348

c2
0.047

p-value
<0.000

p-value
0.828

Parasite TS residues
Tyrosine (Tyr342)

Glutamate

Sialic acid-sugar
complex
attached to
host
Covalent intermediate
ready to transfer to Parasite
Glutamic Acid
Parasite TS residues

Fig 2.1 Chemical reaction catalyzed by Trypanosoma cruzi trans sialidase (TcTS)..
Mechanism of removal of sialic acid from host, creating a stable covalent intermediate.
Used with permission from:
http://pubs.rsc.org/en/content/articlehtml/2011/OB/C0OB00826E#imgfig1
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100

TS Group II

100

100

TS Group IV

97
100
100
86

100

TS Group VII
TS Group III

100

76
100

100
91

100

TS Group VI

73
100

TS Group VIII
TS Group I *

* All samples unique to this study resolve in TS Group 1. See Table 1 for list of samples.
Fig 2.2 Best Maximum Likelihood tree reconstruction for the trans-sialidase (TS) protein
family constructed from T. cruzi TS samples and GenBank reference samples for each
representative group for the TS protein family. Boostrap values (0-100) are indicated at
branch nodes.
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Fig 2.3
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319

402

329
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339
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Fig 2.3 Summary of results, showing DNA and amino acid sequence variation, and
results of the analysis of Selecton test for natural selection. Based on analysis of the 10
clone sequences. Rows (identified with ALL CAPITAL LETTERS) indicate:
SELECTON, the Selecton score (Orange is strong positive selection, light pink is neutral
and purple is strong negative selection); POSITION, the amino acid position in the TcTS
protein (our sequences cover amino acids 269-434); AA, the amino acid for each of the
10 clones; and DNA, the corresponding nucleotides for each amino acid. The blue line
shows the Selecton score for each amino acid with the red horizontal line indicating
neutral evolution or no selection. The blue histograms show the conservation of each
amino acid site (1 = no variation, 0 = all sites unique).

PCRp

Catalytic Region (1)
Alpha and Lectin
Region (2)
Clone

Selection Key:

Strongest Positive

Strongest Purifying

Fig. 2.4 Comparison of Selection values between the clone and 48 PCRp sequences.
Orange indicates strong positive selection, yellow is neutral and magenta is strong
negative selection.The catalytic region is outlined in green and the non-catalytic region is
outlined by red.
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C

C

B

B

A

A
D

B

C

C

B

A

A

A = N-terminal catalytic domain
B = Alpha helix domain
C = C-terminal lectin like domain
D = Aromatic sandwich structure

D

Selection Key:

Strongest Positive

Strongest Purifying

Fig. 2.5 Three-dimension projection of Trypanosoma cruzi trans-sialidase (TcTS)
molecule with amino acids shaded to indicate Selection values. A. N-terminal catalytic
domain. B. alpha-helix domain, C. C-terminal lectin-like domain. D. Highlight of
aromatic sandwich (Trp312) of the catalytic domain.
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